

7
8/6/01

Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Bruce L. Daugherty, et al.

Serial No.: (To be assigned) Case 19634YDA Art Unit: 1646

Filed: (To be assigned) Examiner: Prema Mertz

For: EOSINOPHIL EOTAXIN RECEPTOR

The Honorable Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR § 1.97

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

EXPRESS MAIL CERTIFICATE
DATE OF DEPOSIT August 5, 2001
EXPRESS MAIL NO. EL 523910/62US
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS
BEING DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS EXPRESS MAIL "POST OFFICE TO
ADDRESSEE" BEFORE 5 P.M. ON THE ABOVE DATE IN
AN ENVELOPE ADDRESSED TO ASSISTANT COMMISSIONER
FOR PATENTS, WASHINGTON, D.C. 20231
MAILED BY H. B. Crowley
DATE August 6, 2001

This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.


Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the present application.

The references on the attached form PTO-1449 were previously submitted to or cited by the Office in the parent application Serial No. 08/847,296, filed April 24, 1997 (Merck Case No. 19634Y), upon which the instant application relies for an earlier filing date under 35 U.S.C. § 120. Therefore, pursuant to 37 CFR § 1.98(d), copies of these references are not enclosed herewith. Applicants would gladly provide copies of these references upon request.

Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

The Applicants respectfully contend that the application is allowable and a favorable response from the Examiner is earnestly solicited.

Respectfully submitted,

By 
J. Eric Thies
Reg. No. 35,382
Attorney for Applicant

MERCK & CO., INC.
P.O. Box 2000
Rahway, New Jersey 07065-0907
(732) 594-3904

Date: August 6, 2001